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ABSTRACT 
 
Hot-melt extrusion and 3D printing are among the recent means of processing techniques 
adopted in the pharmaceutical industry. These technologies are used to as a method of preparing 
solid dispersions develop complex shapes that are difficult to be obtained using other means of 
production. In the current research work, many formulations loaded with lidocaine HCl were 
prepared and extruded using 11mm twin-screw extruder. The extrudate filaments were then fed 
into a fused deposition modeling (FDM) printer to fabricate mucoadhesive films meant to buccal 
applications to manage local pain within the oral cavity that requires the intervention with local 
anesthetics. The printed films drug content was determined using HPLC, films drug content was 
within the acceptable limits. Furthermore, the drug release was assessed using an in-house 
method. All test formulations revealed an excellent release profile of the lidocaine HCl, reaching 
more than 90% within 5-15 min. The films adhesion and mechanical properties were tested using 
texture analyzer. The results indicated that the films possess an adequate mechanical property to 
satisfy its intended use. In conclusion, this research work demonstrates that coupling hot-melting 
extruder to a fused deposition modelling printing is feasible to produce lidocaine-loaded buccal 
mucoadhesive films intended for local application in the oral cavity. 
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CHAPTER 1 
INTRODUCTION 
 
Hot-melt extrusion (HME) has been known since 1930s and is widely used in the plastics 
industry (Chokshi & Zia, 2014). HME was recently adopted in the pharmaceutical industry mainly 
as a method of creating pharmaceutical solid dispersions. HME, as the name indicates, is based on 
the combining of heat treatment, mixing of materials and extruding the molten material throughout 
an orifice (i.e., pressurizing the materials) where combining these factors in a controlled manner 
exerts the required stress on the treated material to change some of its physical and 
physicochemical criteria, which will serve the purpose of enhancing the performance of the 
material in question. (Bruin, Van Zuilichem, & Stolp, 1978)  
From an engineering point of view, there are two types of extruders, a) single screw 
extruder and b) twin screws extruder, based on the number of screws used in the process 
(Maniruzzaman, Boateng, Snowden, & Douroumis, 2012). Both types consist of the same 
functional parts, which are feeding zone, barrel (in which the elements-loaded-shafts reside and 
rotate to convey and mix the materials), and discharge zone (in this zone different dies can be 
accommodated to yield different shapes of extrudate). When it comes to the elements-loaded-
shafts, it could be assembled into numerous configurations each to serve the desired purpose 
sought by the user. Figure 1 shows two examples of how a screw could be assembled. 
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This diversity in the machinery, in terms of classes, screws configurations, feeding zone 
location, temperature, and speed, gives HME more advantages and preference, since it can be 
employed for different applications (Repka, Majumdar, Battu, Srirangam, & Upadhye, 2008). 
There are other advantages for HME in the pharmaceutical applications, such as its suitability for 
continuous processing, it is a solvent-free process of making solid dispersions, and the equipment 
costs are lower with a smaller footprint compared to other processing equipment used in the 
pharmaceutical industry (Kolter, Karl, & Gryczke, 2012) 
 
 
Figure 1 HME Screw Configurations 
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3-Dimensional Printing  
 
3-Dimensional Printing (3D printing or 3DP), also known as additive manufacturing, is a 
technique used to fabricate objects from an electronic data model – usually created using 
Computer-Aided Design (CAD) software-. The fabricated objects are often challenging to create 
by conventional methods (e.g., objects with complex geometrical properties). 3DP creates such 
objects by laying one layer over another layer in accordance with the CAD model (Ngo, Kashani, 
Imbalzano, Nguyen, & Hui, 2018). One of the earliest types of 3D printers (Stereolithography 
printer) was introduced for commercial use in the late 1980s by 3D Systems (Wohlers & Gornet, 
2016), 3D Systems is considered a pioneer in the development, engineering, and manufacturing of 
3D printing techniques through its internal research and partnerships with other companies 
specialized in creating other techniques of 3D printing (3D-Systems, 2020). This fabrication 
technology has been used in a wide array of fields from construction, to rapid prototyping, to the 
bioprinting of biological tissues (Lee & Yeong, 2016; Tay, et al., 2017). 
Additive manufacturing is classified into seven major classes based on the mechanism of 
layering and curing of materials. The first class is  directed energy deposition, which includes laser 
engineered net shape, direct metal deposition, direct light fabrication, and 3D laser cladding. This 
class employs the most complex fabrication methods, since it relies on a direct energy source to 
bind the layers together. The second class is sheet lamination, which includes laminated object 
manufacturing (LOM) and ultrasonic additive manufacturing (UAM). The third class is powder 
bed fusion, which has five techniques to print; this class use electron beam or laser to fuse the 
powder particles. Selective laser melting (SLM), direct metal laser sintering (DMLS), selective 
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heat sintering (SHS), electron beam melting (EBM), and selective laser sintering (SLS) are 
techniques of powder bed fusion class. The fourth class is material jetting, where the material is 
jetted through a printing head onto a platform to the specified CAD model and allowed to cure by 
exposing it to UV light. Plastics and polymers such as high-density polyethylene (HDPE) and 
polypropylene are used as printing material in material jetting 3DP. The fifth class is binder jetting, 
which involves two materials, binder material and powder material, where the binder material 
functions as an adhesive agent sandwiched between powder layers. The sixth class is 
photopolymerisation, where focused UV light is used to cure photosensitive polymer resin. The 
seventh class, and the one used in this project, is material extrusion, where a thermoplastic filament 
is fed into a printing head in which the temperature is elevated in a controlled manner to soften the 
filament then shape it into the desired geometry. This technology is also known as fused deposition 
modeling (FDM) (ASTM, 2012; Kruth, 1991; Wong & Hernandoz, 2012). 
Buccal Dosage Forms 
 
One can administer medicament into patients by numerous means. However, the easiest 
and the preferable mean of administration is the oral route. Because solid and liquid active 
pharmaceutical ingredients (API) could be administered orally to exert local effect in the oral 
cavity and along the gastrointestinal tract (GIT) or systemic effect as long as the API will be 
sufficiently bioavailable in systemic circulation at a therapeutic level. One of the barriers to 
achieving sufficient bioavailability following oral administration of some APIs is significant 
hepatic clearance (known as first-pass effect). This issue has motivated pharmaceutical scientists 
in academia and industry to continuously seek practical solutions to overcome the effect of the 
first-pass metabolism of certain orally administered APIs (Drummond, Rathbone, & Tucker, 
1994).  
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Among the solutions to the problem of the first-pass effect, is shifting the absorption site 
for the API from the GIT to the oral cavity because of the high vascularity of the oral cavity that 
directly access to the systemic circulation, which allows direct absorption into the systemic 
circulation without crossing the hepatic environment. In this vein, in the past 30 years researchers 
have been intensively studying the suitability and the extent of the lining of the oral cavity, called 
the oral mucosa, to absorb APIs. The anatomy of the oral mucosa that lines the oral cavity consists 
of two main layers, epithelium layer backed by arteries and veins rich connective tissue layer. The 
epithelium is made out of five layers that are mucus layer, stratum distendum, stratum 
filamentosum, stratum suprabasal, and stratum basal; whereas the connective tissue consists of 
lamona propria and is backed with a submucosa as illustrated in Figure 2 (Rathbone, Senel, & 
Pather, 2015).  
  
 
Figure 2 Cross-Section of the oral Lining Histology 
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The total surface area of the oral cavity is reported to be approximately 170 squared cm 
(Colllins & Dawes, 1987), which is relatively small compared to other effective absorption sites 
such as the stomach and the intestines. This makes the systemic bioavailability of the API that 
intended to be absorbed in the oral cavity relatively low. Even though the absorption area in the 
oral cavity is relatively smaller, it still yields better bioavailability compared to topical route (Du, 
Liu, Salentinin, Nguyen, & Boyd, 2014; Squier & Rooney, 1976)  
John Smart (1993) believes that the oral mucosa, despite its high vascularity, is a significant 
barrier that hinders the systemic absorption of the large theraputic molecules but a suitable rout 
for local delivery within the oral cavity. It has been shown that patients who sufer chronic injuries 
within the oral cavity and prescribed a mucoadhesive-dosage-form, do not adhere to the regimen 
for the long term use. The incompliance is attributed to the lack of physical flexibility of the 
commercially available dosage forms (Hearnden, et al., 2012). thus finding a more acceptable 
alternative to improve patients compliance is required. 
Considering the anatomical and physiological nature of the oral cavity and its lining, 
pharmaceutical scientists considered some design criteria of dosage forms intended for oral 
administration and to be absorbed in the oral cavity such as sublingual tablets, buccal 
mucoadhesive films and buccal mucoadhesive tablets. Where it should be manufactured in a 
manner that enhances patient compliance as well as improves the acceptability of such delivery 
systems as an alternative for the conventional oral solid dosage forms. One agreed upon criterion 
is that a mucoadhesive dosage should be unobtrusive and easy to place in the oral cavity and must 
be fabricated in a patient-friendly way that does not eating, tasting and speech . Another agreed 
upon concept is that the excipients embedded in the formulations should not irritate the mucosa to 
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prevent excess saliva section which will results in API wash-out and prevent its availability for 
absorption (Anders & Merkle, 1989). 
This research project is an attempt to couple the HME and FDM 3D printer to produce 
lidocaine HCl mucoadhesive films for local oral application targeting oral ulcers and other 
wounds. This coupling could open the opportunity for continuous manufacturing process of the 
mucoadhesive film based on some of the quality by design (QbD) requirements to ensure the 
quality of the outputs. 
Lidocaine HCl is a white odourless powder. Lidocaine HCl has a melting range between 
74-79°C (USP 29) and water solubility of 0.69 g/ml at room temperature. Lidocaine HCl is 
physicaly and chemically stable in the solid form. However, in solution it has been proven that it 
degrades mainly by hydrolysis (Groningsson, Lindgren, Lundberg, Sandberg, & Wahlen, 1985). 
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CHAPTER 2 
METHODOLOGY 
Materials  
 
Lidocaine HCl (API) and polyethylene glycol 3350 were purchased from Spectrum 
Chemical Manufacturing Corporation (New Brunswick, NJ, USA). PolyOx™ N80 LEO NF 
(PEO N80), hypromellose HME grade (HPMC), and hypromellose acetate succinate 716 
(HPMC-AS) were obtained as gifts from ColorCon Inc. (West Point, PA, USA). All other 
chemicals and solvents were of an analytical grade and purchased from Fisher Scientific 
(Hanover Park IL, USA). 
Formulations Composition 
 
Different formulations were prepared based on the screening design. Each excipient in 
the formulation was set into two levels (Table1). The concentrations of Lidocaine HCl was fixed 
at 10% (w/w) for each formulation. Based on the number of components and levels of each 
component, 16 formulations were suggested (Table 2). 
Table 1 Excipients Levels 
 high [+] low [-] 
PEO 8 5 
HPMC 3 0 
HPMC-AS 4 0 
PEG 2 0 
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Table 2 Formulations composition as per the Screening DoE (%w/w) 
Formulation 
code 
PEO 
N80 
HPMC 
HPMC-
AS 
PEG 
Total 
parts 
Lidocaine 
HCl  
F1 8 3 4 2 17 10 
F2 8 3 4 0 15 10 
F3 8 3 0 2 13 10 
F4 8 3 0 0 11 10 
F5 8 0 4 2 14 10 
F6 8 0 4 0 12 10 
F7 8 0 0 2 10 10 
F8 8 0 0 0 8 10 
F9 5 3 4 2 14 10 
F10 5 3 4 0 12 10 
F11 5 3 0 2 10 10 
F12 5 3 0 0 8 10 
F13 5 0 4 2 11 10 
F14 5 0 4 0 9 10 
F15 5 0 0 2 7 10 
F16 5 0 0 0 5 10 
 
To minimize the number of formulations handled, eight formulations were selected for 
processing and testing. The final candidate formulations are F2, F3, F5, F8, F9, F12, F14, and 
F15. 
Film Preparation 
Hot-Melt Extrusion  
 
The HME process was conducted using Thermo Scientific™ Process 11 Parallel Twin-
Screw Extruder by Thermo Fisher Scientific (Waltham, MA, USA). The produced extrudate 
processed at 140℃ (including Die), Screws speed of 50 RPM and the feeding rate between 1 – 2 
gm/min. The extruder was equipped with 1.7 mm die to produce filaments with suitable diameter 
for 3D printing. 
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3D Printing 
 
The 3D printing step was carried on Prusa i3 MK3 printer (Prague, Czech Republic). The 
printing head temperature was set at 200℃ while the printing bed temperature was set on 40℃. 
The desired shape of the printed film is a cylinder with 6 mm radius and 0.24 mm thickness. The 
dimensions were entered into an on-line designing webpage (TINKERCAD©), the design was 
sliced via Cura© software from Ultimaker (Utrecht, Netherlands).  
Every formulation was printed in three different infill percent (40%, 70%, and 100%) and 
every infill was printed in two infill patterns (grid shape & lines shape), thus every successful 
formulation is printed in 6 different configurations as shown in Table 3. 
Table 3 3DP Film infills and patterns 
                   Infill 
Pattern 
40% 70% 100% 
Lines ✓ ✓ ✓ 
Grid ✓ ✓ ✓ 
 
Once the filament is fed and fixed correctly into the printing-head, the printing-head was 
allowed to reach the required printing temperature of 200°C, then printing to the specified shape 
starts. 
 
Three-Point Bend Test 
 
Using Texture analyzer (TA) TA.XT2i (Stable Micro Systems/Texture Technologies 
Corporation, London, UK) equipped with TA-92N Three-Pint Bend Rig, a 6 cm specimens (n=4) 
of extruded filaments were placed on the rig, a testing knife is lowered to be in contact with the 
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specimen and force was exerted until the specimen broke. Samples were deemed acceptable if it 
broke after 1 sec of applying the force (Zhang, Feng, Patil, Tiwari, & Repka, 2017). 
Drug Content 
 
Samples of physical mixtures, extruded filaments and 3D printed films were analyzed 
(n=3) to assure the drug content and uniformity. The weighted samples (approximately 15-25 mg 
each) were dissolved in 20 mL methanol then diluted 10 times and analyzed using High 
Performance Liquid Chromatography (HPLC). 
Differential Scanning Calorimetry (DSC) 
 
The physical state of the API, excipients, HME extruded filament, and the 3D printed 
films were assessed using TA Instruments (New Castle, DE, USA) where 3 -5 mg samples were 
placed in Tzero pan sealed with accompanying lid. The loaded pan then placed in the DSC. The 
DSC was set to equilibrate at 30°C then to stay in Isothermal state for 1 minute, afterward start to 
ramp 10°C / min until it reaches maximum of 200°C.  
In Vitro Release 
 
The Lidocaine HCl release profile of different 3D printed films was studies using an in-
house method. Since there is no compendial method and apparatus to study the release from 
mucoadhesive films, the literature is rich with customized in-house methods and apparatae to 
study the release profile of various APIs  (Eleftheriadis, et al., 2019). The in-house apparatus is a 
60 mL tube filled with 50 mL Saliva Simulating Fluid (SSF) as a release media, the SSF consists 
of sodium chloride, potassium phosphate monobasic, and sodium phosphate dibasic, kept under 
continuous stirring at 37℃ and pH of 7.2. 
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 Films (n =3) immersed and held at a reasonable depth in the SSF release media by a 
supporting shaft as it shown in Figure 3. A sample of 1 mL is withdrawing then replaced with 
fresh quantity of SSF at predetermined time points (0, 5, 10, 15, 30, 45, 60, 90, and 120 min). 
HPLC was used to analyze the samples.  
 
Figure 3 In-house Release Apparatus 
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HPLC analysis 
 
The HPLC analysis was performed using Waters HPLC-UV system (Waters Corporation, 
Milford, MA, USA). Luna C8 (5µ) 150x4.6 mm column was used. The composition of the used 
mobile phase was Methanol: 25mM Dibasic Potassium Phosphate (k2HPO4) buffer in 70:30 % 
(v/v). The pH was adjusted to 6.8 using o-phosphoric acid. The lidocaine HCl was detected by 
using 20 µL injection volume and 0.8 mL/min flow rate at 225 nm. Under these analytical 
conditions, the lidocaine HCl retention time of approximately 6.3 minutes.  The method linearity 
was validated over wide range of lidocaine HCl concentrations (1, 5, 10, 25, 50, and 100 µg/mL) 
and the R2 was 0.9999. 
Film Strength  
 
Using Texture analyzer (TA) TA.XT2i (Stable Micro Systems/Texture Technologies 
Corporation, London, UK) equipped with TA-108S-5 Probe, a 150x15mm 3D printed film was 
placed on the holding tray with holes beneath the film to allow the probe to pass through the film 
and measure the required force to break through the film. Once fixed on the tray the test is run in 
the following TA conditions:  
• Pre-test speed = 2.00mm/sec. 
• Test Speed = 1.00 mm/sec. 
• Distance = 10.0 mm. 
• Trigger force = 10.0 g. 
• Break sensitivity = 50 g.  
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Folding Endurance  
 
Folding endurance is a test to assess the mechanical elasticity of the film, where a film 
strip is fixed on surface and then folded 90° repeatedly in the same point until the film at this 
point comes to full break (Irfan, et al., 2016). 3D printed films (n=3) of each formulation were 
fixed then manually folded 90° repeatedly until complete break of the film. The number of 
foldings until the sample broke was reported. 
Adhesion  
 
Using Texture analyzer (TA) TA.XT2i (Stable Micro Systems/Texture Technologies 
Corporation, London, UK) equipped with TA-57R 7mm Die, 1" radius prop, the adhesion study 
was conducted as follows: a 150x15mm 3D printed film was wetted for 30 seconds and 5 min by 
SSF then the wetted film is placed on a holding tray. Once fixed on the tray the test starts as per 
the following conditions:  
• Pre-test speed = 1.00mm/sec 
• Test Speed = 1.00 mm/sec 
• Applied Force = 356.9 g 
• Return Distance = 10 mm 
• Contact time = 5 sec 
• Trigger Type = Auto 
• Trigger Force = 51.0 g 
• Tare mode = Auto  
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Figure 4 is a schematic presentation of the workflow in this research project. Figure 4 and 
summarizes the processes and the related tests in respect to each other. 
 
Figure 4 Project Flow Chart 
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CHAPTER 3 
RESULTS AND DISCUSSION  
Film Preparation 
HME 
 
The screw configuration identified as “standard” on Figure 1 was used. The torque in all 
processed formulations was between 25 -37 per cent which indicates that the formulations were 
malleable enough and suitable for HME processing. The obtained filaments were faint yellow to 
light brownish yellow depending on the formulation composition, all filaments showed similar 
texture and were smooth to the touch. 
Three-Point Bend Test 
 
This test was conducted to assess the extruded filament suitability for 3D printing 
process, formulations that failed this test were disqualified for further processing. Of every 
formulation 4 samples (n=4) underwent the test and the time to break should not be less than 
(NLT) 1 sec because any filament that breaks in less than 1 second is deemed fragile and could 
break inside the 3D printer and clog it. Table 4 shows the results of three-point bend test of the 
extruded formulations. 
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Table 4 Three-Point Bend results 
Formulations 
Time 
(sec)  
n=4 
S. D 
F2 1.76 0.21 
F3 1.75 0.18 
F5 1.73 0.06 
F8 1.74 0.29 
F9 1.76 0.05 
F12 0.44 0.06 
F14 1.74 0.07 
F15 1.61 0.01 
 
 
All formulations, except F12, exceeded the 1.5 sec mark, which allows them to have the 
necessary stiffness to be fed and processed in the 3D printer. Thus, F12 was excluded because it 
failed to meet the acceptance criteria (i.e. out of Specifications) of NLT 1 sec and broke at 0.4 
sec. 
3D Printing 
 
The physical appearance of the 3D printed films was a porous cylindrical film with a 6 
mm radius and 0.24 mm thickness. Using the online designing software (TINKERCAD©) and 
0
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Figure 5  Three-Point Bend results 
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the slicing software Cura© software from Ultimaker (Utrecht, Netherlands), the following was 
entered for the printing dimensions: 
• X axis = 12 mm. 
• Y axis = 12 mm. 
• Z axis = 0.24 mm. 
• Layer Thickness = 0.06 mm. 
• Wall Thickness = 0.8 mm. 
• Wall number = 1 
 
 
Formulations F2, F3, F5, F8, F9, F14, and F15 extrudates were examined for diameter 
uniformity because during the extrusion process some variability in the diameter occurs due to 
pull tension during the filament collection step. Once the diameter uniformity of the filament is 
proven satisfactory, the 3D printing step starts by feeding the filament into the FDM 3D printer.  
 Films printed from formulations F3, F5, F8, F9, and F15 couldn’t maintain the physical 
shape specifications because of the viscosity being too high to be printed and shaped. whereas 
formulations prepared with the lower level of plasticizer were too fragile so that they broke 
during the feeding in the 3D printer, thus they were not suitable for the project’s objective.  Only 
formulations F2 and formulation F14 succeeded to meet the specified physical shape and to 
maintain the suitable physical strength to be handled for further testing. The final 3D printed film 
of F2 and F14 is depicted in Figures 6 and 7, respectively. 
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Figure 6 F2 3DP films 
 
 
Figure 7 F14 3DP films 
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Drug Content 
 
The drug content of filaments before 3D printing was within the acceptance limits. As 
Table 5 and Figure 8 shows, the API content in formulation F2 was 90%±6.92, which is at the 
lower borderline of the acceptance limit. The F14 content was around 94%±7.63. Possible 
reasons for the low assay values are discussed below 
 
Table 5 Filaments Content of Lidocaine HCl 
Filament 
Content 
% 
(n=3) 
S. D 
F2 90.00 6.92 
F14 94.00 7.63 
 
 
Figure 8 Filaments Content of Lidocaine HCl 
 
The 3D printed films’ content was uniform throughout the different infill percent of F2 
films around 88% of the label claim, which is 2% lower than the filament content before printing 
this reduction in Lidocaine HCl content pre- and post 3D printing process was expected because 
of the repeated exposure to different processing force. In the other hand, the drug content of F14 
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3D printed films of 40% and 70% infills were about 6% less than the filament where the 3D 
printed films content was 88% and 90%, respectively. However, the 100% infill films of 
formulation F14 showed extremely lower content (more than 10% lower) compared to the other 
3D printed films of 40% and 70% infill, wherein it was expected that the 100% infill to show the 
highest content of them all since it’s the one with more material and weight in it. The 100% infill 
content was 79% (i.e. 14% lower than the filament content before printing) which could be 
attributed to various reasons, such as 3D printing using filament part with initial low load of the 
API due to non-uniform mixing and distribution , but this reason was ruled out since the other 
two infills were 3D printed using the same filament and with a reasonable content, therefore if it 
was true one of the other infills should’ve shown relatively higher content to balance the non-
uniform API distribution out.  
Other possible cause of low content in the 100% infill films is that the incomplete 
extraction of the API from the tested films which resulted in the observed lower content. 
Regardless of the content of the 100% infill printed film of F14, the content of the remaining 3D 
printed films of both formulations deemed satisfactory as shown and depicted in Table 6 and 
Figure 9 below.  
Table 6 3DP Films Content of Lidocaine HCl 
 Infill 
(%) 
Content 
(%) 
(n=3) 
S. D 
F2 
40 88.53 1.52 
70 88.63 0.04 
100 88.28 4.18 
F14 
40 88.04 4 
70 90.06 6.89 
100 79.23 2 
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Figure 9  3DP Films Content of Lidocaine HCl 
 
DSC 
The final pharmaceutical product in this project is exposed to relatively elevated 
temperatures during different manufacturing steps. therefore, phase transition is of great 
importance to be checked in the different stages of the manufacturing of the 3D printed films. 
DSC was conducted for Pure API as well as pure excipient before conducting it for every 
formulation in its different forms as Physical mixture, Filament, and 3D printed films.  
 API, Lidocaine HCl, melting point is around 80°C (NIH, 2020), the DSC analysis show 
a peak for the pure API corresponding to that melting point, Relatively smaller peaks are seen in 
the physical mixtures of both formulations and that could be attributed to the small load of the 
API in the final formulation (10%). However, the API peak disappears after exposing to elevated 
temperatures as seen in extruded filaments and 3D printed Films, which indicates Lidocaine HCl 
converted from crystalline form into amorphous form upon the HME and 3D printing processes. 
This amorphous dispersion explains the high aqueous solubility which is reflected as high release 
profile in short period.   
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Figure 10 DSC Curves 
 
In Vitro Release 
 
The release studies were conducted over 2 hours period where a sample withdrawn every 
15 minutes in the first hour, then every 30 minutes in the second hour for F2 samples, the 
observed release was a raid release profile where all samples showed almost identical release 
behavior regardless of the infill shape and percent, where all samples released more than 85% 15 
min then increased slightly up to the 30 min time point then plateaued at 90% until the end of the 
second hour. Table 7 and Figures 11 and 12 show F2 samples release profile. 
Table 7 F2 Films Release 
 100 Lines 70 Grid 40 Lines 
Time (min) Release % S. D Release % S. D Release % S. D 
0 0.0 0.00 0.0 0.00 0.0 0.00 
15 87.5 4.91 90.9 1.84 91.5 0.85 
30 90.6 1.04 91.1 2.07 91.4 1.00 
45 90.6 1.05 91.5 1.13 91.1 0.87 
60 90.6 1.13 91.3 1.04 91.2 1.06 
90 90.5 1.15 91.3 1.00 91.0 1.13 
120 90.5 1.19 91.0 1.01 90.3 1.47 
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Figure 11 F2 Films Release Profile 
 
 
Figure 12 Detailed Release Profile of F2 films 
 
Due to the rapid release observed in F2 samples within the first 15 min, the release 
behavior between time point 0 min and 15 min was investigated to compare it to the profile 
observed for F14, therefore two additional sampling time points that is 5 min and 10 min has 
been added in the F14 Release study. As Table 8 and Figures 13 and 14 shows, the release 
profile of F14 samples was similar to that observed in F2 but in earlier onset. Release of 95% of 
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all samples observed at the 5 min mark in F14 then increased to the maximum release amount at 
the 10 min mark then plateaued afterward to the end of the second hour instead of 15 min in F2 
then increased slightly up to the 30 min time point then plateaued at  until the end of the second 
hour. 
Table 8 F14 Films Release 
  100 Grid 70 Lines 40 Grid 
Time (min) Release % S. D Release % S. D Release % S. D 
0 0.00 0.00 0.00 0.00 0.00 0.00 
5 97.83 9.76 94.42 5.22 97.73 4.43 
10 101.36 11.64 95.51 6.35 97.94 4.36 
15 101.86 11.87 95.59 6.54 97.90 4.28 
30 101.86 11.84 94.88 7.09 97.85 4.34 
45 101.86 11.80 95.34 6.71 97.72 4.31 
60 101.71 11.75 95.28 6.51 97.66 4.34 
90 101.60 11.75 95.18 6.60 97.58 4.29 
120 101.72 11.73 95.06 6.59 97.45 4.35 
 
 
Figure 13 F14 Films Release Profile 
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Figure 14 Detailed Release Profile of F14 films 
Film Strength  
 
The film strength is a mechanical feature that assessed to assure that 3D printed film 
shows enough durability during handling and shipping. Films strength observed to be 
proportional to the infill percent where films of 100% infill from both formulations showed the 
highest strength compared to the 70% and 40% infills. The higher the infill the stronger the film. 
Table 9 3DP Films Strength 
n=5 
infill 
% 
Strength (g) 
Stiffness 
(g/Sec) 
F2 
40 287.796 152.474 
70 543.700 357.589 
100 1430.327 741.324 
F14 
40 123.071 109.282 
70 178.457 112.131 
100 372.596 327.653 
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Folding Endurance  
 
The results of the folding endurance test for the 3D printed films showed sufficient 
mechanical durability and elasticity of the finished pharmaceutical product. Three films of each 
infill from each formulation were folded until completely broken, it is worth to mention that the 
infill pattern of all films used in this test is the lines pattern. The results are depicted in Table 10 
and Figure 15 below. The results suggest that as the higher the infill percent, the more durable 
and tolerant the film becomes. Which help in the patient’s compliance issue steamed from the 
lack of physical flexibility. 
Table 10 Folding Times to Break 
 100% 70% 40% 
F2 152 ± 31 173 ±19 135 ±11 
F14 149 ±25 131 ±22 54 ±10 
 
Figure 15 3DP films Folding Endurance 
 
Adhesion  
 
Samples adhesion was assessed over two stages of wetting, the first stage was after 
wetting the samples for 30 seconds in SSF, the second stage was after 5 minutes of immersing 
the samples in the SSF to simulate the wetting behavior in the oral cavity over the administration 
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period. As depicted in Table 11 and Table 12, F2 and F14 samples which were wetted for 30 sec, 
once wetted and fixed, they required four times the force (represented by the peak force) to 
detach the samples from the surface compared to the samples wetted for 5 min, however samples 
from both formulations in both stages showed similarity on the parameters of adhesiveness, and 
work of adhesion results, but the stringiness was four times higher in samples wetted for 5 min, 
because samples were hydrated due to the HPMC existence in the formulation (Patil, Tiwari, & 
Repka, 2016) that makes it softer and  relatively pliable.  
Due to the absence of a marketed, pharmaceutically equivalent, reference-product to 
compare the 3D printed films to, these results of adhesion will be used as the acceptance 
specification as well as the standard used in future studies.  
 
 
Table 11 Adhesion Results After 30 sec of Wetting 
n=5 
Infill 
% 
peak force 
(N) 
Adhesiveness  
work of 
adhesion 
(N.mm) 
stringiness 
(mm) 
F2 
40 4.57 2.57 0.82 1.02 
70 4.86 2.14 0.68 1.17 
100 4.48 2.77 0.60 0.94 
F14 
40 3.05 2.61 0.36 1.15 
70 4.09 2.81 0.57 1.55 
100 3.76 1.51 0.36 0.28 
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Table 12 Adhesion Results After 5 min of Wetting 
n=5 
Infill 
% 
peak force 
(N) 
Adhesiveness  
work of 
adhesion 
(N.mm) 
stringiness 
(mm) 
F2 
40 1.439 2.542 0.497 3.297 
70 1.932 2.352 0.843 4.12 
100 2.807 1.934 1.267 4.453 
F14 
40 1.326 2.193 0.462 4.007 
70 1.616 2.438 0.552 3.136 
100 2.699 2.099 0.873 0.84 
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CHAPTER 4  
CONCLUSION 
 
Mucoadhesive 3D printed lidocaine film were successfully produced using HME extruded 
Filament and FDM 3D printer. The films characterization yielded satisfactory results in term of 
lidocaine content and its release from the film in SSF. Furthermore, the mechanical criteria of the 
films met established conditions. The films showed sufficient strength and good adhesion profile 
over to different stages of wetting by SSF.
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